

Cigna Healthcare Medicare Advantage Prior Authorization Changes For Health Care Providers



October 2023

This list is not all-inclusive. Additional codes may be added when new codes are released from Centers for Medicare & Medicaid Services (CMS) or the American Medical Association (AMA).

***Removal from prior authorization is not a guarantee of payment. Codes may be subject to code editing, benefit plan exclusions, and post-service review for coverage.**

Code	Code description	Addition/removal
0421T	Under prostate ablation procedure	Addition 10/1/2023
28292	Correction hallux valgus	Addition 10/1/2023
28296	Correction, hallux valgus (bunion), with or without sesamoidectomy; with metatarsal osteotomy (e.g., Mitchell, Chevron, or concentric type procedures).	Addition 10/1/2023
30420	Rhinoplasty, primary; including major septal repair.	Addition 10/1/2023
30465	Repair of nasal vestibular stenosis (e.g., spreader grafting, lateral nasal wall reconstruction).	Addition 10/1/2023
30520	Septoplasty or submucous resection, with or without cartilage scoring, contouring or replacement with graft.	Addition 10/1/2023
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant.	Addition 10/1/2023
52442	Cystourethro with additional implant.	Addition 10/1/2023
58542	Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s).	Addition 10/1/2023
58571	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s).	Addition 10/1/2023
58573	Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s).	Addition 10/1/2023
66180	Aqueous shunt eye with graft.	Addition 10/1/2023
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach.	Addition 10/1/2023
67917	Repair eyelid defect.	Addition 10/1/2023

Code	Code description	Addition/removal
A2003	Bio-connekt wound matrix, per square centimeter.	Removal 7/31/2023
B4105	In-line cartridge containing digestive enzyme(s) for enteral feeding, each.	Removal 7/31/2023
B4187	Omegaven, 10 grams lipids.	Removal 7/31/2023
C1823	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads.	Removal 7/31/2023
C1824	Generator, cardiac contractility modulation (implantable).	Removal 7/31/2023
C1839	Iris prosthesis	Removal 7/31/2023
C1840	Lens, intraocular (telescopic).	Removal 7/31/2023
C1841	Retinal prosthesis, includes all internal and external components.	Removal 7/31/2023
C2644	Brachytherapy source, cesium-131 chloride solution, per millicurie.	Removal 7/31/2023
C2645	Brachytherapy planar source, palladium-103, per square millimeter.	Removal 7/31/2023
C8926	Transesophageal echocardiography (TEE) with contrast for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report.	Removal 7/31/2023
C8927	Transesophageal echocardiography (TEE) with contrast for monitoring purposes, including probe placement, real-time two-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate-time basis.	Removal 7/31/2023
C9727	Insertion of implants into the soft palate; minimum of three implants.	Removal 7/31/2023
C9757	Laminotomy (hemilaminectomy) with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar.	Removal 7/31/2023
C9758	Blinded procedure for NYHA class iii/iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study.	Removal 7/31/2023
G0448	Insertion or replacement of a permanent pacing cardioverter-defibrillator system with transvenous lead(s), single or dual chamber with insertion of pacing electrode, cardiac venous system, for left ventricular pacing.	Removal 7/31/2023

Code	Code description	Addition/removal
G2000	Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, noncovered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session.	Removal 7/31/2023
G2069	Medication-assisted treatment, buprenorphine (injectable); weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2070	Medication-assisted treatment, buprenorphine (implant insertion); weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2071	Medication-assisted treatment, buprenorphine (implant removal); weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2072	Medication-assisted treatment, buprenorphine (implant insertion and removal); weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2073	Medication-assisted treatment, naltrexone; weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2075	Medication-assisted treatment, medication not otherwise specified; weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 7/31/2023
G2088	Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes (list separately in addition to code for primary procedure).	Removal 7/31/2023
J0591	Injection, deoxycholic acid, 1 mg.	Removal 7/31/2023
J0597	Injection, C1 esterase inhibitor (human), BERINERT®, 10 units.	Removal 7/31/2023
J0879	Injection, difelikefalin, 0.1 microgram, (for ESRD on dialysis).	Removal 7/31/2023
J1460	Injection, gamma globulin, intramuscular, 1 cc.	Removal 7/31/2023
J1560	Injection, gamma globulin, intramuscular, over 10 cc.	Removal 7/31/2023

Code	Code description	Addition/removal
J1632	Injection, brexanolone, 1 mg.	Removal 7/31/2023
J2425	Injection, palifermin, 50 micrograms.	Removal 7/31/2023
J7177	Injection, human fibrinogen concentrate (fibryga), 1 mg.	Removal 7/31/2023
J7178	Injection, human fibrinogen concentrate, 1 mg.	Removal 7/31/2023
J7311	Fluocinolone acetonide, intravitreal implant.	Removal 7/31/2023
Q0481	Microprocessor control unit for use with electric ventricular assist device, replacement only.	Removal 7/31/2023
Q2026	Injection, RADIESSE®, 0. 1 ml.	Removal 7/31/2023
0465T	Suprachoroidal injection of a pharmacologic agent (does not include supply of medication).	Removal 10/1/2023
0479T	Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children.	Removal 10/1/2023
20560	Needle insertion(s) without injection(s); one or two muscle(s).	Removal 10/1/2023
20561	Needle insertion(s) without injection(s); three or more muscles.	Removal 10/1/2023
21073	Manipulation of temporomandibular joint(s) (TMJ), therapeutic, requiring an anesthesia service (i.e., general or monitored anesthesia care).	Removal 10/1/2023
21499	Unlisted musculoskeletal procedure, head.	Removal 10/1/2023
25020	Decompression fasciotomy, forearm and/or wrist; flexor or extensor compartment.	Removal 10/1/2023
26989	Unlisted procedure, hands or fingers.	Removal 10/1/2023
27197	Closed treatment of posterior pelvic ring fracture(s), dislocation(s), diastasis or subluxation of the ilium, sacroiliac joint, and/or sacrum, with or without anterior pelvic ring fracture(s) and/or dislocation(s) of the pubic symphysis and/or superior/inferior rami, unilateral or bilateral; without manipulation.	Removal 10/1/2023
27198	Closed treatment of posterior pelvic ring fracture(s), dislocation(s), diastasis or subluxation of the ilium, sacroiliac joint, and/or sacrum, with or without anterior pelvic ring fracture(s) and/or dislocation(s) of the pubic symphysis and/or superior/inferior rami, unilateral or bilateral; with manipulation, requiring more than local anesthesia (i.e., general anesthesia, moderate sedation, spinal/epidural).	Removal 10/1/2023
29799	Unlisted procedure, casting or strapping.	Removal 10/1/2023
32999	Unlisted procedure, lungs and pleura.	Removal 10/1/2023
36468	Single or multiple injections of sclerosing solutions, spider veins (telangiectasia); limb or trunk.	Removal 10/1/2023

Code	Code description	Addition/removal
42699	Unlisted procedure, salivary glands or ducts.	Removal 10/1/2023
44799	Unlisted procedure, intestine.	Removal 10/1/2023
45999	Unlisted procedure, rectum.	Removal 10/1/2023
46601	Anoscopy; diagnostic, with high-resolution magnification (HRA) (e.g., colposcope, operating microscope) and chemical agent enhancement, including collection of specimen(s) by brushing or washing, when performed.	Removal 10/1/2023
46607	Anoscopy; with high-resolution magnification (HRA) (e.g., colposcope, operating microscope) and chemical agent enhancement, with biopsy, single or multiple.	Removal 10/1/2023
47399	Unlisted procedure, liver.	Removal 10/1/2023
48999	Unlisted procedure, pancreas.	Removal 10/1/2023
49999	Unlisted procedure, abdomen, peritoneum and omentum.	Removal 10/1/2023
53454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume.	Removal 10/1/2023
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming.	Removal 10/1/2023
70558	Magnetic resonance (e.g., proton) imaging, brain (including brain stem and skull base), during open intracranial procedure (e.g., to assess for residual tumor or residual vascular malformation); with contrast material(s).	Removal 10/1/2023
76499	Unlisted diagnostic radiologic procedure	Removal 10/1/2023
81181	ATXN7 (ataxin 7) (e.g., spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81182	ATXN8OS (ATXN8 opposite strand [non-protein coding]) (e.g., spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81243	FMR1 (fragile X mental retardation 1) (e.g., fragile X mental retardation) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81271	HTT (huntingtin) (e.g., Huntington disease) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81343	PPP2R2B (protein phosphatase 2 regulatory subunit beta) (e.g., spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81371	HLA Class I and II typing, low resolution (e.g., antigen equivalents); HLA-A, -B, and -DRB1/3/4/5 (e.g., verification typing).	Removal 10/1/2023
84999	Unlisted chemistry procedure	Removal 10/1/2023

Code	Code description	Addition/removal
90867	Therapeutic repetitive transcranial magnetic stimulation treatment; planning.	Removal 10/1/2023
90868	Therapeutic repetitive transcranial magnetic stimulation treatment; delivery and management, per session.	Removal 10/1/2023
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold redetermination with delivery and management.	Removal 10/1/2023
91113	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), colon, with interpretation and report.	Removal 10/1/2023
91299	Unlisted diagnostic gastroenterology procedure	Removal 10/1/2023
92499	Unlisted ophthalmological service or procedure	Removal 10/1/2023
93319	3D echocardiographic imaging and post-processing during transesophageal echocardiography, or during transthoracic echocardiography for congenital cardiac anomalies, for the assessment of cardiac structure(s) (e.g., cardiac chambers and valves, left atrial appendage, interatrial septum, interventricular septum) and function, when performed (list separately in addition to code for echocardiographic imaging).	Removal 10/1/2023
93356	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (list separately in addition to codes for echocardiography imaging).	Removal 10/1/2023
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).	Removal 10/1/2023
96920	Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm.	Removal 10/1/2023
96921	Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm.	Removal 10/1/2023
96922	Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm.	Removal 10/1/2023
G0248	Demonstration, prior to initial use, of home INR monitoring for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: face-to-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient ability to perform testing prior to its use.	Removal 10/1/2023
G0249	Provision of test materials and equipment for home INR monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes provision of materials for use in the home and reporting of test results to physician; not occurring more frequently than once a week.	Removal 10/1/2023
G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen.	Removal 10/1/2023

Code	Code description	Addition/removal
G2068	Medication-assisted treatment, buprenorphine (oral); weekly bundle, including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 10/1/2023
G2074	Medication-assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program).	Removal 10/1/2023
G2076	Intake activities, including initial medical examination that is a complete, fully documented physical evaluation and initial assessment by a program physician or a primary care physician, or an authorized health care professional under the supervision of a program physician qualified personnel that includes preparation of a treatment plan that includes the patient's short-term goals and the tasks the patient must perform to complete the short-term goals; the patient's requirements for education, vocational rehabilitation, and employment; and the medical, psychosocial, economic, legal, or other supportive services that a patient needs, conducted by qualified personnel (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure.	Removal 10/1/2023
G2077	Periodic assessment; assessing periodically by qualified personnel to determine the most appropriate combination of services and treatment (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure.	Removal 10/1/2023
G2079	Take-home supply of buprenorphine (oral); up to an additional seven-day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure.	Removal 10/1/2023
G2080	Each additional 30 minutes of counseling in a week of medication-assisted treatment, (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure.	Removal 10/1/2023
G2086	Office-based treatment for opioid use disorder, including development of the treatment plan, care coordination, individual therapy and group therapy and counseling; at least 70 minutes in the first calendar month.	Removal 10/1/2023
G2087	Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month.	Removal 10/1/2023
J3396	Injection, verteporfin, 0.1 mg.	Removal 10/1/2023

Code	Code description	Addition/removal
0004M	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score.	Removal 10/1/2023
0006M	Oncology (hepatic), mRNA expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier.	Removal 10/1/2023
0007M	Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index.	Removal 10/1/2023
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service.	Removal 10/1/2023
0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin-fixed paraffin-embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified.	Removal 10/1/2023
0013U	Oncology (solid organ neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, fresh or frozen tissue or cells, report of specific gene rearrangement(s).	Removal 10/1/2023
0016U	Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation.	Removal 10/1/2023
0017U	Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected.	Removal 10/1/2023
0018M	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score.	Removal 10/1/2023
0023U	Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin	Removal 10/1/2023
0027U	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15.	Removal 10/1/2023
0030U	Drug metabolism (warfarin drug response), targeted sequence analysis (i.e., CYP2C9, CYP4F2, VKORC1, rs12777823).	Removal 10/1/2023

Code	Code description	Addition/removal
0031U	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2) (e.g., drug metabolism) gene analysis, common variants (i.e., *1F, *1K, *6, *7).	Removal 10/1/2023
0032U	COMT (catechol-O-methyltransferase)(e.g., drug metabolism) gene analysis, c.472G>A (rs4680) variant.	Removal 10/1/2023
0033U	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (e.g., citalopram metabolism) gene analysis, common variants (i.e., HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G]).	Removal 10/1/2023
0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (e.g., thiopurine metabolism) gene analysis, common variants (i.e., TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5).	Removal 10/1/2023
0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative.	Removal 10/1/2023
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative.	Removal 10/1/2023
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity.	Removal 10/1/2023
0040U	BCR/ABL1 (t(9;22)) (e.g., chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative.	Removal 10/1/2023
0041U	Borrelia burgdorferi, antibody detection of five recombinant protein groups, by immunoblot, IgM.	Removal 10/1/2023
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG.	Removal 10/1/2023
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to four recombinant protein groups, by immunoblot, IgM.	Removal 10/1/2023
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to four recombinant protein groups, by immunoblot, IgG.	Removal 10/1/2023
0046U	FLT3 (FMS-related tyrosine kinase 3) (e.g., acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative.	Removal 10/1/2023
0049U	NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, quantitative.	Removal 10/1/2023
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service.	Removal 10/1/2023
0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	Removal 10/1/2023

Code	Code description	Addition/removal
0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative.	Removal 10/1/2023
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis.	Removal 10/1/2023
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score.	Removal 10/1/2023
0072U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., CYP2D6-2D7 hybrid gene) (list separately in addition to code for primary procedure).	Removal 10/1/2023
0073U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., CYP2D7-2D6 hybrid gene) (list separately in addition to code for primary procedure).	Removal 10/1/2023
0074U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., non-duplicated gene when duplication/multiplication is trans) (list separately in addition to code for primary procedure).	Removal 10/1/2023
0075U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., 5SQUOTE gene duplication/multiplication) (list separately in addition to code for primary procedure).	Removal 10/1/2023
0076U	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism) gene analysis, targeted sequence analysis (i.e., 3SQUOTE gene duplication/ multiplication) (list separately in addition to code for primary procedure).	Removal 10/1/2023
0078U	Pain management (opioid-use disorder) genotyping panel, 16 common variants (i.e., ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder.	Removal 10/1/2023
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service.	Removal 10/1/2023

Code	Code description	Addition/removal
0083U	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations.	Removal 10/1/2023
0107U	Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method.	Removal 10/1/2023
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species.	Removal 10/1/2023
0110U	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected.	Removal 10/1/2023
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene.	Removal 10/1/2023
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and two bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	Removal 10/1/2023
0116U	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug-to-drug interactions for prescribed medications.	Removal 10/1/2023
0117U	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain.	Removal 10/1/2023
0121U	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood.	Removal 10/1/2023
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood.	Removal 10/1/2023
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling.	Removal 10/1/2023
0136U	ATM (ataxia telangiectasia mutated) (e.g., ataxia telangiectasia) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0137U	PALB2 (partner and localizer of BRCA2) (e.g., breast and pancreatic cancer) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023

Code	Code description	Addition/removal
0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected.	Removal 10/1/2023
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, four resistance genes, one pan gram-negative bacterial target, one pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected.	Removal 10/1/2023
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, six resistance genes, one pan gram-positive bacterial target, one pan Candida target), amplified probe technique, each target reported as detected or not detected.	Removal 10/1/2023
0143U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0144U	Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0145U	Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0146U	Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0147U	Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023

Code	Code description	Addition/removal
0148U	Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0149U	Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0150U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments, including sample validation, per date of service.	Removal 10/1/2023
0154U	FGFR3 (fibroblast growth factor receptor 3) gene analysis (i.e., p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3).	Removal 10/1/2023
0155U	PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (e.g., breast cancer) gene analysis (i.e., p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y).	Removal 10/1/2023
0157U	APC (APC regulator of WNT signaling pathway) (e.g., familial adenomatous polyposis [FAP]) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0158U	MLH1 (mutL homolog 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0159U	MSH2 (mutS homolog 2) (e.g., hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0160U	MSH6 (mutS homolog 6) (e.g., hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0161U	PMS2 (PMS1 homolog 2, mismatch repair system component) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (list separately in addition to code for primary procedure).	Removal 10/1/2023
0162U	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (list separately in addition to code for primary procedure).	Removal 10/1/2023

Code	Code description	Addition/removal
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas.	Removal 10/1/2023
0165U	Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation.	Removal 10/1/2023
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism) gene analysis, common variants.	Removal 10/1/2023
0171U	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence.	Removal 10/1/2023
0173U	Psychiatry (i.e., depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes.	Removal 10/1/2023
0177U	Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status.	Removal 10/1/2023
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons.	Removal 10/1/2023
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1.	Removal 10/1/2023
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10.	Removal 10/1/2023
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19.	Removal 10/1/2023
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2.	Removal 10/1/2023
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4.	Removal 10/1/2023

Code	Code description	Addition/removal
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2.	Removal 10/1/2023
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2.	Removal 10/1/2023
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4.	Removal 10/1/2023
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2.	Removal 10/1/2023
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3.	Removal 10/1/2023
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6.	Removal 10/1/2023
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9.	Removal 10/1/2023
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26.	Removal 10/1/2023
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8.	Removal 10/1/2023
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (i.e., exon 13).	Removal 10/1/2023
0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3.	Removal 10/1/2023
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1.	Removal 10/1/2023
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5.	Removal 10/1/2023
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAPP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12.	Removal 10/1/2023
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3.	Removal 10/1/2023

Code	Code description	Addition/removal
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2.	Removal 10/1/2023
0205U	Ophthalmology (age-related macular degeneration), analysis of three gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements.	Removal 10/1/2023
0206U	Neurology (Alzheimer's disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer's disease.	Removal 10/1/2023
0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities.	Removal 10/1/2023
0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.	Removal 10/1/2023
0218U	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants.	Removal 10/1/2023
0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (i.e., protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility.	Removal 10/1/2023
0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score.	Removal 10/1/2023
0221U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene.	Removal 10/1/2023
0222U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3.	Removal 10/1/2023
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation.	Removal 10/1/2023

Code	Code description	Addition/removal
0229U	BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (e.g., colorectal cancer) promoter methylation analysis.	Removal 10/1/2023
0230U	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), full sequence analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions.	Removal 10/1/2023
0232U	CSTB (cystatin B) (e.g., progressive myoclonic epilepsy type 1A, Unverricht-Lundborg disease), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions.	Removal 10/1/2023
0233U	FXN (frataxin) (e.g., Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions.	Removal 10/1/2023
0235U	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome), full gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, mobile element insertions, and variants in non-uniquely mappable regions.	Removal 10/1/2023
0246U	Red blood cell antigen typing, DNA, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens.	Removal 10/1/2023
0252U	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy.	Removal 10/1/2023
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (e.g., pre-receptive, receptive, post-receptive).	Removal 10/1/2023
0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested.	Removal 10/1/2023

Code	Code description	Addition/removal
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative.	Removal 10/1/2023
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping.	Removal 10/1/2023
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score.	Removal 10/1/2023
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of seven gene pathways (ER, AR, PI3K, MAPK, HH, TGF β , Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score.	Removal 10/1/2023
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, α -ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD).	Removal 10/1/2023
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping.	Removal 10/1/2023
0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants.	Removal 10/1/2023
0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes.	Removal 10/1/2023
0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing.	Removal 10/1/2023

Code	Code description	Addition/removal
0268U	Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0269U	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0270U	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0271U	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day).	Removal 10/1/2023
0272U	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood, buccal swab, or amniotic fluid, comprehensive.	Removal 10/1/2023
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming.	Removal 10/1/2023
0273U	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of eight genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAU), blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0274U	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0276U	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0277U	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).	Removal 10/1/2023

Code	Code description	Addition/removal
0278U	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal swab, or amniotic fluid.	Removal 10/1/2023
0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes.	Removal 10/1/2023
0285U	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score.	Removal 10/1/2023
0286U	CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (e.g., drug metabolism) gene analysis, common variants.	Removal 10/1/2023
0287U	Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high).	Removal 10/1/2023
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and three reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score.	Removal 10/1/2023
0289U	Neurology (Alzheimer's disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0290U	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0294U	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score.	Removal 10/1/2023
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing of at least 20 molecular features (e.g., human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy.	Removal 10/1/2023

Code	Code description	Addition/removal
0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification.	Removal 10/1/2023
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification.	Removal 10/1/2023
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification.	Removal 10/1/2023
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification.	Removal 10/1/2023
0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD.	Removal 10/1/2023
0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of three biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD.	Removal 10/1/2023
0312U	Autoimmune diseases (e.g., systemic lupus erythematosus [SLE]), analysis of eight IgG autoantibodies and two cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment.	Removal 10/1/2023
0313T	Vagus nerve-blocking therapy (morbid obesity); laparoscopic revision or replacement of vagal trunk neurostimulator electrode array, including connection to existing pulse generator.	Removal 10/1/2023
0313U	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (i.e., negative, low probability of neoplasia or positive, high probability of neoplasia).	Removal 10/1/2023
0314T	Vagus nerve-blocking therapy (morbid obesity); laparoscopic removal of vagal trunk neurostimulator electrode array and pulse generator.	Removal 10/1/2023

Code	Code description	Addition/removal
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and three housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (i.e., benign, intermediate, malignant).	Removal 10/1/2023
0316T	Vagus nerve-blocking therapy (morbid obesity); replacement of pulse generator.	Removal 10/1/2023
0317T	Vagus nerve-blocking therapy (morbid obesity); neurostimulator pulse generator electronic analysis, includes reprogramming when performed.	Removal 10/1/2023
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer.	Removal 10/1/2023
0318U	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood.	Removal 10/1/2023
0319U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection.	Removal 10/1/2023
0320U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	Removal 10/1/2023
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique.	Removal 10/1/2023
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report.	Removal 10/1/2023
0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer.	Removal 10/1/2023
0347T	Placement of interstitial device(s) in bone for radiostereometric analysis (RSA).	Removal 10/1/2023
0348T	Radiologic examination, radiostereometric analysis (RSA); spine, (includes, cervical, thoracic and lumbosacral, when performed).	Removal 10/1/2023
0349T	Radiologic examination, radiostereometric analysis (RSA); upper extremity(ies), (includes shoulder, elbow and wrist, when performed).	Removal 10/1/2023

Code	Code description	Addition/removal
0350T	Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee and ankle, when performed).	Removal 10/1/2023
0352T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred.	Removal 10/1/2023
0354T	Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred.	Removal 10/1/2023
0358T	Bioelectrical impedance analysis whole body composition assessment, supine position, with interpretation and report.	Removal 10/1/2023
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead).	Removal 10/1/2023
0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system.	Removal 10/1/2023
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system.	Removal 10/1/2023
0419T	Destruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibroma.	Removal 10/1/2023
0420T	Destruction neurofibroma, extensive, (cutaneous, dermal extending into subcutaneous); trunk and extremities, extensive, greater than 100 neurofibroma.	Removal 10/1/2023
0422T	Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral.	Removal 10/1/2023
0434T	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea.	Removal 10/1/2023
0435T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session.	Removal 10/1/2023
0436T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study.	Removal 10/1/2023
0447T	Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision.	Removal 10/1/2023

Code	Code description	Addition/removal
0472T	Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (e.g., retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional.	Removal 10/1/2023
0473T	Device evaluation and interrogation of intra-ocular retinal electrode array (e.g., retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional.	Removal 10/1/2023
0480T	Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; each additional 100 cm ² , or each additional 1% of body surface area of infants and children, or part thereof (list separately in addition to code for primary procedure).	Removal 10/1/2023
0481T	Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed.	Removal 10/1/2023
0487T	Biomechanical mapping, transvaginal, with report.	Removal 10/1/2023
0491T	Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; first 20 sq cm or less.	Removal 10/1/2023
0492T	Ablative laser treatment, non-contact, full field and fractional ablation, open wound, per day, total treatment surface area; each additional 20 sq cm, or part thereof (list separately in addition to code for primary procedure).	Removal 10/1/2023
0493T	Near-infrared spectroscopy studies of lower extremity wounds (e.g., for oxyhemoglobin measurement).	Removal 10/1/2023
0506T	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report.	Removal 10/1/2023
0507T	Near infrared dual imaging (i.e., simultaneous reflective and transilluminated light) of meibomian glands, unilateral or bilateral, with interpretation and report.	Removal 10/1/2023
0508T	Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia.	Removal 10/1/2023
0533T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for six days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report.	Removal 10/1/2023
0534T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for six days up to 10 days; set-up, patient training, configuration of monitor.	Removal 10/1/2023

Code	Code description	Addition/removal
0535T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for six days up to 10 days; data upload, analysis and initial report configuration.	Removal 10/1/2023
0536T	Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for six days up to 10 days; download review, interpretation and report.	Removal 10/1/2023
0547T	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score.	Removal 10/1/2023
0552T	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional.	Removal 10/1/2023
0553T	Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention.	Removal 10/1/2023
0558T	Computed tomography scan taken for the purpose of biomechanical computed tomography analysis.	Removal 10/1/2023
0559T	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure.	Removal 10/1/2023
0560T	Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (list separately in addition to code for primary procedure).	Removal 10/1/2023
0561T	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide.	Removal 10/1/2023
0562T	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (list separately in addition to code for primary procedure).	Removal 10/1/2023
0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral.	Removal 10/1/2023
0564T	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations.	Removal 10/1/2023
0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation.	Removal 10/1/2023
0566T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint, including ultrasound guidance, unilateral.	Removal 10/1/2023

Code	Code description	Addition/removal
0567T	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound.	Removal 10/1/2023
0568T	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound.	Removal 10/1/2023
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional.	Removal 10/1/2023
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter.	Removal 10/1/2023
0577T	Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters).	Removal 10/1/2023
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance.	Removal 10/1/2023
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia.	Removal 10/1/2023
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (e.g., electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, one to three parameters.	Removal 10/1/2023
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (e.g., electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, four or more parameters.	Removal 10/1/2023
0596T	Temporary female intraurethral valve-pump (i.e., voiding prosthesis); initial insertion, including urethral measurement.	Removal 10/1/2023

Code	Code description	Addition/removal
0597T	Temporary female intraurethral valve-pump (i.e., voiding prosthesis); replacement.	Removal 10/1/2023
0602T	Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent.	Removal 10/1/2023
0603T	Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours.	Removal 10/1/2023
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed.	Removal 10/1/2023
0692T	Therapeutic ultrafiltration.	Removal 10/1/2023
0696T	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation.	Removal 10/1/2023
0700T	Molecular fluorescent imaging of suspicious nevus; first lesion.	Removal 10/1/2023
0701T	Molecular fluorescent imaging of suspicious nevus; each additional lesion (list separately in addition to code for primary procedure).	Removal 10/1/2023
0717T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs.	Removal 10/1/2023
0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral.	Removal 10/1/2023
0719T	Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment.	Removal 10/1/2023
0725T	Vestibular device implantation, unilateral.	Removal 10/1/2023
0727T	Removal and replacement of implanted vestibular device, unilateral.	Removal 10/1/2023
0728T	Diagnostic analysis of vestibular implant, unilateral; with initial programming.	Removal 10/1/2023
0729T	Diagnostic analysis of vestibular implant, unilateral; with subsequent programming	Removal 10/1/2023

Code	Code description	Addition/removal
0735T	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (list separately in addition to code for primary procedure).	Removal 10/1/2023
15786	Abrasion; single lesion (e.g., keratosis, scar).	Removal 10/1/2023
20910	Cartilage graft; costochondral.	Removal 10/1/2023
20932	Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (list separately in addition to code for primary procedure).	Removal 10/1/2023
20933	Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (i.e., hemicylindrical) (list separately in addition to code for primary procedure).	Removal 10/1/2023
20934	Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (i.e., cylindrical) (list separately in addition to code for primary procedure).	Removal 10/1/2023
21076	Impression and custom preparation; surgical obturator prosthesis.	Removal 10/1/2023
21899	Unlisted procedure, neck or thorax.	Removal 10/1/2023
22999	Unlisted procedure, abdomen, musculoskeletal system.	Removal 10/1/2023
31899	Unlisted procedure, trachea, bronchi.	Removal 10/1/2023
33419	Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; additional prosthesis(es) during same session (list separately in addition to code for primary procedure).	Removal 10/1/2023
33866	Aortic hemiarch graft, including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (list separately in addition to code for primary procedure).	Removal 10/1/2023
36299	Unlisted procedure, vascular injection.	Removal 10/1/2023
38242	Bone marrow or blood-derived peripheral stem cell transplantation; allogeneic donor lymphocyte infusions.	Removal 10/1/2023
40799	Unlisted procedure, lips.	Removal 10/1/2023
40899	Unlisted procedure, vestibule of mouth.	Removal 10/1/2023
41599	Unlisted procedure, tongue, floor of mouth.	Removal 10/1/2023
42299	Unlisted procedure, palate, uvula.	Removal 10/1/2023
42999	Unlisted procedure, pharynx, adenoids, or tonsils.	Removal 10/1/2023

Code	Code description	Addition/removal
44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen.	Removal 10/1/2023
47550	Biliary endoscopy, intraoperative (choledochoscopy) (list separately in addition to code for primary procedure).	Removal 10/1/2023
47999	Unlisted procedure, biliary tract.	Removal 10/1/2023
67345	Chemodeneration of extraocular muscle.	Removal 10/1/2023
68400	Incision, drainage of lacrimal gland.	Removal 10/1/2023
68899	Unlisted procedure, lacrimal system.	Removal 10/1/2023
69949	Unlisted procedure, inner ear.	Removal 10/1/2023
77299	Unlisted procedure, therapeutic radiology clinical treatment planning.	Removal 10/1/2023
78399	Unlisted musculoskeletal procedure, diagnostic nuclear medicine.	Removal 10/1/2023
78456	Acute venous thrombosis imaging, peptide.	Removal 10/1/2023
81105	Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P).	Removal 10/1/2023
81106	Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-2a/b (T145M).	Removal 10/1/2023
81107	Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIB/IIIa complex], antigen CD41 [GPIIb]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-3a/b (I843S).	Removal 10/1/2023
81108	Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-4a/b (R143Q).	Removal 10/1/2023
81109	Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha 2 subunit of VLA-2 receptor] [GPIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant (eg, HPA-5a/b [K505E]).	Removal 10/1/2023

Code	Code description	Addition/removal
81110	Human Platelet Antigen 6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-6a/b (R489Q).	Removal 10/1/2023
81111	Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41] [GPIIb]) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-9a/b (V837M).	Removal 10/1/2023
81112	Human Platelet Antigen 15 genotyping (HPA-15), CD109 (CD109 molecule) (e.g., neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-15a/b (S682Y).	Removal 10/1/2023
81167	BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (i.e., detection of large gene rearrangements).	Removal 10/1/2023
81168	CCND1/IGH (t(11;14)) (e.g., mantle cell lymphoma) translocation analysis, major breakpoint, qualitative and quantitative, if performed.	Removal 10/1/2023
81171	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81172	AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (e.g., expanded size and methylation status).	Removal 10/1/2023
81174	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant.	Removal 10/1/2023
81185	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (e.g., spinocerebellar ataxia) gene analysis; full gene sequence.	Removal 10/1/2023
81186	CACNA1A (calcium voltage-gated channel subunit alpha1 A) (e.g., spinocerebellar ataxia) gene analysis; known familial variant.	Removal 10/1/2023
81187	CNBP (CCHC-type zinc finger nucleic acid binding protein) (e.g., myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81188	CSTB (cystatin B) (e.g., Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles.	Removal 10/1/2023
81189	CSTB (cystatin B) (e.g., Unverricht-Lundborg disease) gene analysis; full gene sequence.	Removal 10/1/2023

Code	Code description	Addition/removal
81190	CSTB (cystatin B) (e.g., Unverricht-Lundborg disease) gene analysis; known familial variant(s).	Removal 10/1/2023
81192	NTRK2 (neurotrophic receptor tyrosine kinase 2) (e.g., solid tumors) translocation analysis.	Removal 10/1/2023
81193	NTRK3 (neurotrophic receptor tyrosine kinase 3) (e.g., solid tumors) translocation analysis.	Removal 10/1/2023
81200	ASPA (aspartoacylase) (e.g., Canavan disease) gene analysis, common variants (e.g., E285A, Y231X).	Removal 10/1/2023
81202	APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants.	Removal 10/1/2023
81204	AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (e.g., expanded size or methylation status).	Removal 10/1/2023
81205	BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (e.g., maple syrup urine disease) gene analysis, common variants (e.g., R183P, G278S, E422X).	Removal 10/1/2023
81209	BLM (Bloom syndrome, RecQ helicase-like) (e.g., Bloom syndrome) gene analysis, 2281del6ins7 variant.	Removal 10/1/2023
81221	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; known familial variants.	Removal 10/1/2023
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; duplication/deletion variants.	Removal 10/1/2023
81224	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g., cystic fibrosis) gene analysis; intron 8 poly-T analysis (e.g., male infertility).	Removal 10/1/2023
81234	DMPK (DM1 protein kinase) (e.g., myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles.	Removal 10/1/2023
81237	EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (e.g., diffuse large B-cell lymphoma) gene analysis, common variant(s) (e.g., codon 646).	Removal 10/1/2023
81239	DMPK (DM1 protein kinase) (e.g., myotonic dystrophy type 1) gene analysis; characterization of alleles (e.g., expanded size).	Removal 10/1/2023
81244	FMR1 (Fragile X mental retardation 1) (e.g., fragile X mental retardation) gene analysis; characterization of alleles (e.g., expanded size and methylation status).	Removal 10/1/2023
81247	G6PD (glucose-6-phosphate dehydrogenase) (e.g., hemolytic anemia, jaundice), gene analysis; common variant(s) (e.g., A, A-).	Removal 10/1/2023

Code	Code description	Addition/removal
81248	G6PD (glucose-6-phosphate dehydrogenase) (e.g., hemolytic anemia, jaundice), gene analysis; known familial variant(s).	Removal 10/1/2023
81252	GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (e.g., nonsyndromic hearing loss) gene analysis; full gene sequence.	Removal 10/1/2023
81253	GJB2 (gap junction protein, beta 2, 26kDa; connexin 26) (e.g., nonsyndromic hearing loss) gene analysis; known familial variants.	Removal 10/1/2023
81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (e.g., nonsyndromic hearing loss) gene analysis, common variants (e.g., 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)]).	Removal 10/1/2023
81255	HEXA (hexosaminidase A [alpha polypeptide]) (e.g., Tay-Sachs disease) gene analysis, common variants (e.g., 1278insTATC, 1421+1G>C, G269S).	Removal 10/1/2023
81258	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant.	Removal 10/1/2023
81260	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (e.g., familial dysautonomia) gene analysis, common variants (e.g., 2507+6T>C, R696P).	Removal 10/1/2023
81264	IGK@ (Immunoglobulin kappa light chain locus) (e.g., leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s).	Removal 10/1/2023
81265	Comparative analysis using short tandem repeat (STR) markers; patient and comparative specimen (e.g., pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [e.g., buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells).	Removal 10/1/2023
81266	Comparative analysis using short tandem repeat (STR) markers; each additional specimen (e.g., additional cord blood donor, additional fetal samples from different cultures, or additional zygosity in multiple birth pregnancies) (list separately in addition to code for primary procedure).	Removal 10/1/2023
81267	Chimerism (engraftment) analysis, post-transplantation specimen (e.g., hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection.	Removal 10/1/2023
81268	Chimerism (engraftment) analysis, post-transplantation specimen (e.g., hematopoietic stem cell), includes comparison to previously performed baseline analyses; with cell selection (e.g., CD3, CD33), each cell type.	Removal 10/1/2023

Code	Code description	Addition/removal
81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants.	Removal 10/1/2023
81273	KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (e.g., mastocytosis), gene analysis, D816 variant(s).	Removal 10/1/2023
81274	HTT (huntingtin) (e.g., Huntington disease) gene analysis; characterization of alleles (e.g., expanded size).	Removal 10/1/2023
81278	IGH@/BCL2 (t(14;18)) (e.g., follicular lymphoma) translocation analysis, major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative.	Removal 10/1/2023
81284	FXN (frataxin) (e.g., Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles.	Removal 10/1/2023
81285	FXN (frataxin) (e.g., Friedreich ataxia) gene analysis; characterization of alleles (e.g., expanded size).	Removal 10/1/2023
81289	FXN (frataxin) (e.g., Friedreich ataxia) gene analysis; known familial variant(s).	Removal 10/1/2023
81290	MCOLN1 (mucopolipin 1) (e.g., Mucopolipidosis, type IV) gene analysis, common variants (e.g., IVS3-2A>G, del6.4kb).	Removal 10/1/2023
81293	MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants.	Removal 10/1/2023
81296	MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants.	Removal 10/1/2023
81299	MSH6 (mutS homolog 6 [E. coli]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants.	Removal 10/1/2023
81303	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; known familial variant.	Removal 10/1/2023
81304	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; duplication/deletion variants.	Removal 10/1/2023
81305	MYD88 (myeloid differentiation primary response 88) (e.g., Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant.	Removal 10/1/2023
81308	PALB2 (partner and localizer of BRCA2) (e.g., breast and pancreatic cancer) gene analysis; known familial variant.	Removal 10/1/2023
81313	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (e.g., prostate cancer).	Removal 10/1/2023

Code	Code description	Addition/removal
81315	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; common breakpoints (e.g., intron 3 and intron 6), qualitative or quantitative.	Removal 10/1/2023
81316	PML/RARalpha, (t(15;17)), (promyelocytic leukemia/retinoic acid receptor alpha) (e.g., promyelocytic leukemia) translocation analysis; single breakpoint (e.g., intron 3, intron 6 or exon 6), qualitative or quantitative.	Removal 10/1/2023
81318	PMS2 (postmeiotic segregation increased 2 [<i>S. cerevisiae</i>]) (e.g., hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants.	Removal 10/1/2023
81320	PLCG2 (phospholipase C gamma 2) (e.g., chronic lymphocytic leukemia) gene analysis, common variants (e.g., R665W, S707F, L845F).	Removal 10/1/2023
81322	PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant.	Removal 10/1/2023
81326	PMP22 (peripheral myelin protein 22) (e.g., Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant.	Removal 10/1/2023
81327	SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis.	Removal 10/1/2023
81330	SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (e.g., Niemann-Pick disease, Type A) gene analysis, common variants (e.g., R496L, L302P, fsP330).	Removal 10/1/2023
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis.	Removal 10/1/2023
81333	TGFBI (transforming growth factor beta-induced) (e.g., corneal dystrophy) gene analysis, common variants (e.g., R124H, R124C, R124L, R555W, R555Q).	Removal 10/1/2023
81336	SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy) gene analysis; full gene sequence.	Removal 10/1/2023
81337	SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy) gene analysis; known familial sequence variant(s).	Removal 10/1/2023
81341	TRB@ (T-cell antigen receptor, beta) (e.g., leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (e.g., Southern blot).	Removal 10/1/2023
81345	TERT (telomerase reverse transcriptase) (e.g., thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (e.g., promoter region).	Removal 10/1/2023
81346	TYMS (thymidylate synthetase) (e.g., 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (e.g., tandem repeat variant).	Removal 10/1/2023

Code	Code description	Addition/removal
81348	SRSF2 (serine and arginine-rich splicing factor 2) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (e.g., P95H, P95L).	Removal 10/1/2023
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis.	Removal 10/1/2023
81353	TP53 (tumor protein 53) (e.g., Li-Fraumeni syndrome) gene analysis; known familial variant.	Removal 10/1/2023
81357	U2AF1 (U2 small nuclear RNA auxiliary factor 1) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variants (e.g., S34F, S34Y, Q157R, Q157P).	Removal 10/1/2023
81360	ZRSR2 (zinc finger CCCH-type, RNA binding motif and serine/arginine-rich 2) (e.g., myelodysplastic syndrome, acute myeloid leukemia) gene analysis, common variant(s) (e.g., E65fs, E122fs, R448fs).	Removal 10/1/2023
81361	HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, hemoglobinopathy); common variant(s) (e.g., HbS, HbC, HbE).	Removal 10/1/2023
81362	HBB (hemoglobin, subunit beta) (e.g., sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s).	Removal 10/1/2023
81375	HLA Class II typing, low resolution (e.g., antigen equivalents); HLA-DRB1/3/4/5 and -DQB1.	Removal 10/1/2023
81376	HLA Class II typing, low resolution (e.g., antigen equivalents); one locus (e.g., HLA-DRB1/3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each.	Removal 10/1/2023
81377	HLA Class II typing, low resolution (e.g., antigen equivalents); one antigen equivalent, each.	Removal 10/1/2023
81379	HLA Class I typing, high resolution (i.e., alleles or allele groups); complete (i.e., HLA-A, -B, and -C).	Removal 10/1/2023
81419	Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2.	Removal 10/1/2023
81438	Hereditary neuroendocrine tumor disorders (e.g., medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL.	Removal 10/1/2023
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score.	Removal 10/1/2023

Code	Code description	Addition/removal
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score.	Removal 10/1/2023
81507	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy.	Removal 10/1/2023
81508	Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score.	Removal 10/1/2023
81510	Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score.	Removal 10/1/2023
81511	Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing).	Removal 10/1/2023
81512	Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score.	Removal 10/1/2023
81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for <i>Atopobium vaginae</i> , <i>Gardnerella vaginalis</i> , and <i>Lactobacillus</i> species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.	Removal 10/1/2023
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for <i>Gardnerella vaginalis</i> , <i>Atopobium vaginae</i> , <i>Megasphaera</i> type 1, <i>Bacterial Vaginosis Associated Bacteria-2 (BVAB-2)</i> , and <i>Lactobacillus</i> species (<i>L. crispatus</i> and <i>L. jensenii</i>), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of <i>Trichomonas vaginalis</i> and/or <i>Candida</i> species (<i>C. albicans</i> , <i>C. tropicalis</i> , <i>C. parapsilosis</i> , <i>C. dubliniensis</i>), <i>Candida glabrata</i> , <i>Candida krusei</i> , when reported.	Removal 10/1/2023
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (list separately in addition to code for primary procedure).	Removal 10/1/2023
81560	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score.	Removal 10/1/2023

Code	Code description	Addition/removal
86950	Leukocyte transfusion	Removal 10/1/2023
88375	Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session.	Removal 10/1/2023
89335	Cryopreservation, reproductive tissue, testicular.	Removal 10/1/2023
89344	Storage (per year); reproductive tissue, testicular/ovarian.	Removal 10/1/2023
89354	Thawing of cryopreserved; reproductive tissue, testicular/ovarian.	Removal 10/1/2023
89356	Thawing of cryopreserved; oocytes, each aliquot.	Removal 10/1/2023
91117	Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, e.g., meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report.	Removal 10/1/2023
93592	Percutaneous transcatheter closure of paravalvular leak; each additional occlusion device (list separately in addition to code for primary procedure).	Removal 10/1/2023
93998	Unlisted noninvasive vascular diagnostic study.	Removal 10/1/2023
94799	Unlisted pulmonary service or procedure.	Removal 10/1/2023
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter.	Removal 10/1/2023
J7316	Injection, ocriplasmin, 0.125 mg.	Removal 10/1/2023
J9210	Injection, emapalumab-lzsg, 1 mg.	Removal 10/1/2023
K1007	Bilateral hip, knee, ankle, foot device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors.	Removal 10/1/2023
L8608	Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system.	Removal 10/1/2023
L8698	Miscellaneous component, supply or accessory for use with total artificial heart system.	Removal 10/1/2023
P9099	Blood component or product not otherwise classified.	Removal 10/1/2023
V2629	Prosthetic eye, other type.	Removal 10/1/2023
81212	BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants	Removal 10/1/2023
81215	BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant	Removal 10/1/2023
81217	BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis; known familial variant	Removal 10/1/2023

Code	Code description	Addition/removal
81417	Exome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (e.g., updated knowledge or unrelated condition/syndrome)	Removal 10/1/2023
89346	Storage, (per year); oocyte	Removal 10/1/2023
G0162	Skilled services by a registered nurse (RN) in the delivery of management and evaluation of the plan of care; each 15 minutes (the patient's underlying condition or complication requires an RN to ensure that essential non-skilled care achieve its purpose in the home health or hospice setting)	Removal 10/1/2023
J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Removal 10/1/2023
J0598	Injection, C1 esterase inhibitor (human), 10 units	Removal 10/1/2023
J0599	Injection, C1 esterase inhibitor (human), (haegarda), 10 units	Removal 10/1/2023
J0638	Injection, canakinumab, 1 mg	Removal 10/1/2023
J1290	Injection, ecallantide, 1 mg	Removal 10/1/2023
J1301	Injection, edaravone, 1 mg	Removal 10/1/2023
J2503	Injection, pegaptanib sodium, 0.3 mg	Removal 10/1/2023
J3397	Injection, vestronidase alfa-vjbk, 1 mg	Removal 10/1/2023
L8691	Auditory osseointegrated device, external sound processor, replacement	Removal 10/1/2023
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)	Removal 10/1/2023